Creative Medical Technology (NASDAQ:CELZ) Upgraded by Wall Street Zen to “Hold” Rating

by · The Markets Daily

Wall Street Zen upgraded shares of Creative Medical Technology (NASDAQ:CELZ – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Other research analysts have also recently issued reports about the company. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. Weiss Ratings lowered Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold”.

Get Our Latest Analysis on Creative Medical Technology

Creative Medical Technology Trading Up 1.1%

CELZ opened at $0.96 on Friday. The company has a market cap of $6.33 million, a P/E ratio of -0.46 and a beta of 2.04. The company’s 50 day moving average is $1.01 and its 200-day moving average is $1.68. Creative Medical Technology has a 1-year low of $0.62 and a 1-year high of $6.25.

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, equities analysts forecast that Creative Medical Technology will post -1.18 EPS for the current year.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

(Get Free Report)

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.

Read More